However, less encouraging results came from the phase II, Keynote-086 trial, where previously treated metastatic triple negative patients demonstrated an ORR of only 5.3% in the entire cohort population, and only 5.7% amongst the 60% of patients with PD-L1 positive tumours (although in cohort B—1st line TNBC PD-L1+ group, ORR = 23.1%) [86]. This evidence concerns the gene CD274 and neoplasm.